Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Viking Therapeutics Inc

Start price
Target price
Perf. (%)
€69.50
29.04.24
€100.00
31.03.26
-0.75%
03.05.24

Could be very worthwhile Investment >20% year
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€3.73
25.04.24
-
25.04.25
0.80%
27.04.24

Risky Investment
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.60
25.04.24
-
25.04.25
-2.00%
27.04.24

Could be worthwhile Investment >10% per year
buy
Mersana Therapeutics

Start price
Target price
Perf. (%)
€2.68
24.04.24
-
24.04.25
4.63%
26.04.24

Could be worthwhile Investment >10% per year
buy
Plug Power Inc.

Start price
Target price
Perf. (%)
€2.49
23.04.24
€3.00
23.04.25
-8.41%
27.04.24

Good rating
Growths much faster than the competition
Leading role in innovation
Very good company culture
buy
Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.07
19.04.24
-
19.04.25
-10.90%
28.04.24

Could be very worthwhile Investment >20% year
buy
Albemarle Corp

Start price
Target price
Perf. (%)
€108.34
17.04.24
-
17.04.25
6.44%
02.05.24

Growths faster than the competition
buy
aTyr Pharma Inc

Start price
Target price
Perf. (%)
€1.66
14.04.24
-
14.04.25
-13.86%
28.04.24

Could be worthwhile Investment >10% per year
Inotiv Inc.

Start price
Target price
Perf. (%)
€5.50
13.04.24
€4.00
13.04.25
-32.36%
27.04.24

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Little Investments for future growth
Cassava Sciences Inc.

Start price
Target price
Perf. (%)
€22.07
13.04.24
€2.00
13.04.25
-5.44%
27.04.24

Probably not worthwhile Investment
EBIT decline/stagnation expected
negative Cash Flow expected
Bad rating
buy
Snap-On Inc.

Start price
Target price
Perf. (%)
€271.90
12.04.24
-
12.04.25
0.11%
13.04.24

Nektar Therapeutics

Start price
Target price
Perf. (%)
€1.50
11.04.24
-
11.04.25
3.27%
14.04.24

Risky Investment
buy
Meta Platforms Inc.

Start price
Target price
Perf. (%)
€484.15
11.04.24
-
11.04.25
-1.43%
13.04.24

buy
Meta Platforms Inc.

Start price
Target price
Perf. (%)
€484.15
11.04.24
-
11.04.25
-1.43%
13.04.24

buy
Meta Platforms Inc.

Start price
Target price
Perf. (%)
€484.15
11.04.24
-
11.04.25
-1.43%
13.04.24

buy
Plug Power Inc.

Start price
Target price
Perf. (%)
€2.91
08.04.24
€3.00
08.04.25
-21.66%
27.04.24

Good rating
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
buy
Cytokinetics Inc.

Start price
Target price
Perf. (%)
€66.50
07.04.24
-
07.04.25
0.75%
14.04.24

Could be very worthwhile Investment >20% year
buy
Advanced Micro Devices Inc.

Start price
Target price
Perf. (%)
€163.46
04.04.24
€165.00
04.04.25
-9.04%
27.04.24

Could be worthwhile Investment >10% per year
Top 10 in its market
Small cyclical dependencies
Future proof or reliable business model
buy
Advanced Micro Devices Inc.

Start price
Target price
Perf. (%)
€163.46
04.04.24
€165.00
04.04.25
-9.04%
27.04.24

Could be worthwhile Investment >10% per year
Top 10 in its market
Small cyclical dependencies
Future proof or reliable business model
buy
Advanced Micro Devices Inc.

Start price
Target price
Perf. (%)
€163.46
04.04.24
€165.00
04.04.25
-9.04%
27.04.24

Could be worthwhile Investment >10% per year
Top 10 in its market
Small cyclical dependencies
Future proof or reliable business model
buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€160.66
04.04.24
-
04.04.25
-0.09%
13.04.24

buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€160.66
04.04.24
-
04.04.25
-0.09%
13.04.24

buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€160.66
04.04.24
-
04.04.25
-0.09%
13.04.24

buy
Cal-Maine Foods Inc.

Start price
Target price
Perf. (%)
€55.84
04.04.24
-
04.04.25
2.94%
13.04.24

Occidental Petroleum Corp.

Start price
Target price
Perf. (%)
€61.99
02.04.24
€55.00
02.04.25
5.50%
13.04.24

Probably not worthwhile Investment
Low dividend yield expected
Lower EBIT Margin than peer group
Revenue decline/stagnation expected